Overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2) is associated with poor prognosis in breast cancer and predicts response to anti-HER2 therapy in breast cancer. The prognostic relevance of moderate expression of HER2 is unclear. Data of 9872 patients with primary nonmetastatic breast cancer from the cancer registries of Magdeburg and Halle, Germany, were analyzed retrospectively. A total of 5907 patients with complete data sets including follow-up were eligible for analysis. HER2 status was determined as recommended by international guidelines. Of 5907 patients investigated, 5023 (68.4%) had HER2 0 and 1C expression and 884 (12.0%) had HER2 (2C)/ HER2K expression. Patients with hormone receptor positive (HRC) and HER2 (2C) tumors had a shorter median disease-free survival (DFS; P!0.0001) and breast cancer specific survival (BCSS; PZ0.019) than HRC patients with HER2 (0/1C) tumors. Among patients with HRK breast cancer there was no significant difference between HER2 (2C) and HER2 (0/1C) tumors. In multivariate analysis after adjustment for other prognostic factors, HER2 (2C) status remained an unfavorable prognostic factor for DFS (hazard ratio (HR)Z1.217, 95% CIZ1.052-1.408; PZ0.008) but not for BCSS (HRZ1.045, 95% CIZ0.926-1.178; PZ0.474). The HER2 (2C) status is an unfavorable prognostic factor for survival of patients with HRC breast cancer. The impact of anti-HER2 therapy in this group of patients should be evaluated.
Introduction
The human epidermal growth factor receptor 2 (HER2) is a cell surface transmembrane receptor. HER2 amplification occurs in 20-30% of invasive breast cancers (Akiyama et al. 1986 , Slamon et al. 1987 , 1989 , Gasparini et al. 1994 and is associated with poor prognosis (Slamon et al. 1987 , Ross & Fletcher 1998 , Berry et al. 2000 , Gennari et al. 2008 . The HER2 status is not only a prognostic but also a predictive factor for response to the anti-HER2 therapy, e.g., trastuzumab (Slamon et al. 2011) . Based on standardized criteria, HER2 expression has been divided on the basis of immunohistochemical (IHC) results into the following groups: 0, 1C, 2C, and 3C (Jacobs et al. 1999) . It is believed that HER2 tumors scored 0 and 1C do not respond to trastuzumab therapy. On the contrary, a HER2 (3C) status implies strong expression of the receptor and is highly predictive for a response to this drug (Ross & Fletcher 1998 , Wolff et al. 2007 . The moderate group of HER2 (2C) cancers requires an additional gene amplification assay (e.g., fluorescent in situ hybridization (FISH) or silver in situ hybridization (SISH) respectively) to identify patients who overexpress HER2 and benefit from anti-HER2 therapy (Ross & Fletcher 1998) . Interestingly, in retrospective analysis with small patient cohorts, the moderate (2C) and low (1C) HER2 expression has been shown to be a negative prognostic survival factor for breast cancer patients (Gilcrease et al. 2009 , Rossi et al. 2012 . Patients with negative HER2 (0) expression demonstrated significantly longer median survival compared to patients with low HER2 (1C) and moderate HER2 (2C) expression respectively. Thus, the prognostic value of moderate HER2 (2C) expression requires reevaluation. In this study we retrospectively analyzed 5907 patients with breast cancer. The HER2 status was compared with clinical and pathological characteristics. The clinical outcome of patients with moderate HER2 (2C) expression was compared with that of HER2 negative (0/1C) patients. We identified 9872 female patients with primary nonmetastatic invasive breast cancer. In 2526 cases the HER2 status was unknown and these patients were excluded from this study (Fig. 1) 
Patients and methods

Patients
Statistical analysis
The statistical calculations were performed using SPSS version 21.0 (SPSS). The association between HER2 status and clinical and pathological variables was assessed using the c 2 test or Fisher's exact test. The DFS and BCSS probability distribution was studied by the KaplanMeier method. The equality of survival curves was tested by the log rank test. DFS was defined as the time between primary diagnosis and disease recurrence of all types as well as breast cancer specific death. BCSS was defined as the time between primary diagnosis and breast cancer specific death. Patients who died of other causes or patients lacking follow-up data were censored. Univariate Cox proportional hazards regression analysis was used to identify significant prognostic factors and then the prognostic significance was evaluated using multivariate analysis. The statistical analyses were two sided and P values of !0.05 were considered statistically significant. Figure 2 DFS probability according to HER2 status. DFS in the whole cohort (A), HRC (B), and HRK (C) breast cancer is demonstrated. The log rank test was used to calculate the P value. HER2, human epidermal growth factor receptor 2; DFS, disease-free survival.
Results
Study design
Between January 2003 and December 2013, 9872 women with primary non-metastatic invasive breast cancer underwent medical treatment in nine hospitals. Patients with unknown HER2 status (nZ2526) and patients with positive HER2 expression defined as HER2 (3C) or HER2 (2C) by IHC and positive HER2C amplification by FISH or SISH (HER2 (2C)/HER2C) (nZ1439) had to be excluded (Fig. 1) . The remaining 5907 patients with a median age of 63 years (range 19-101 years) were eligible for analysis. Patients were divided into two groups based on their HER2 expression and HER2 gene amplification (Fig. 1) . Table 1 summarizes patient and tumor characteristics according to the HER2 IHC-score. Clinical data including surgery, chemotherapy, and hormonal therapy were also analyzed with regard to the HER2 score.
HER2 status and patient and tumor characteristics
Patient and tumor characteristics showed significant differences between the two groups. Moderate HER2 (2C) expression was associated with larger tumor size (P!0.0001), positive lymph node status (PZ0.017), invasive ductal histologic type (PZ0.019), higher tumor grade (P!0.0001), increased expression of Ki-67, lymph node metastases (PZ0.004) and positive estrogen receptor (ER) (P!0.0001) and progesterone receptor (PR) status (PZ0.039). Patients with moderate HER2 (2C) expression were more likely to receive chemotherapy (PZ0.024) but significantly less likely to receive breast conserving surgery (P!0.0001) followed by radiation (PZ0.005) in comparison to the patients with HER2 (0/1C) negative expression.
HER2 status and survival
HER2 (2C) moderate expression appeared to be a worse prognosticator for DFS in comparison to the HER2 (0/1C) negative cases in view of the first 10 years following diagnosis, without statistical significance ( Fig. 2A,  PZ0.072) . Interestingly, analysis of DFS according to HR status showed that HER2 (2C) moderate expression is an unfavorable prognostic factor in HRC cases (Fig. 2B , P!0.0001) but not in HRK cases (Fig. 2C, PZ0 .470). HER2 (2C) moderate status was not associated with BCSS in the whole cohort (Fig. 3A, PZ0 .659). Patients with HRC and moderate HER2 (2C) expression had been found to be associated with shorter median BCSS than HRC and HER2 (0/1C) negative patients (Fig. 3B, PZ0 .018). In HRK patients, HER2-status had no influence on BCSS (Fig. 3C, 
PZ0.544).
Univariate analysis revealed that HER2 (2C) moderate status was a prognostic factor for poor DFS (hazard ratio (HR)Z1.272, 95% CIZ1.112-1.454; P!0.0001; (Table 2) . Menopausal status, increased tumor size, positive lymph node status, higher histological grade, and the administration of radiotherapy, chemotherapy, and hormonal therapy were associated with worse BCSS (Table 3) .
Discussion
This is the largest study of its kind investigating the impact of HER2 (2C) moderate expression on breast cancer survival. Our data provide evidence that tumors with moderate HER2 (2C) expression with no gene amplification differ from cases with negative or low HER2 expression (0/1C). As expected HER2 positivity (3C) was associated with a poor clinical outcome and aggressive tumor behavior, which is consistent with recently published data (Templeton et al. 2014) . In our study, HRC breast cancer patients with tumors displaying moderate HER2 (2C) expression had a poorer DFS but not BCSS compared with low (1C) or negative (0) HER2 expression, confirming previous findings from smaller cohort studies (Gilcrease et al. 2009 , Iorfida et al. 2012 . In other studies, HER2 (2C) was a prognostic factor only in lymph node positive breast cancer (Menard et al. 2008) . However, the impact of moderate HER2 (2C) expression on DFS by multivariate analysis after adjustment for other prognostic factors has been not shown yet (Menard et al. 2008) . HER2 (2C) moderate status is defined as w500 000 detectable HER2 receptors on the cell surface (Ross & Fletcher 1998 ) required for the activation of underlying intracellular HER2 pathways to drive tumor growth and invasiveness. This hypothesis is supported by the finding that even low levels of HER2 (1C) expression involving 100 000 cell surface receptors (Ross & Fletcher 1998) could be associated with a poor outcome (Camp et al. 2003 , Gilcrease et al. 2009 , Iorfida et al. 2012 . According to our data, HER2 (1C) tumors seem to have characteristics between HER2 (0) and HER2 (2C) cancers suggesting a possible linear correlation between HER2 expression and tumor behavior. Such results have been observed for prostate cancer granted that HER2 overexpression is a rare phenomenon (Minner et al. 2010 ). Tumors with low or moderate expression of HER2 (2C) might be more sensitive to different growth factors stimulating breast cancer cells because HER2 signaling is a key factor in breast cancer proliferation (Ross & Fletcher 1998) . Interestingly, in our survey moderate expression of HER2 (2C) receptor was identified as an unfavorable prognostic factor in patients with HRC tumors but not in those with HRK tumors. As already demonstrated, HER2 expression is inversely related to the expression of HR (ER and PR) and is associated with endocrine resistance (Ross & Fletcher 1998 , Massarweh et al. 2008 . One might speculate that low/moderate expression of HER2 indicates some activity of the HER2 pathway and thus an existing influence on HER2 overexpression is routinely used to predict response to anti-HER2 therapy and at present only patients with an IHC score 3C and gene amplification should receive anti-HER2 therapy (Goldhirsch et al. 2013) . It has been demonstrated that tumors with moderate HER2 (2C) expression without gene amplification do not respond to trastuzumab therapy (Slamon et al. 2011 , Goldhirsch et al. 2013 . However, recently published data suggest that a small number of patients with lower levels of HER2 (1C) may benefit from anti-HER2 treatment (Paik et al. 2008 , Perez et al. 2010 .
The association of low HER2 (1C) expression with patient survival has been investigated in a limited number of small sample-sized retrospective studies. Menard et al. (2008) conducted a retrospective study and were able to show that the HER2 (2C) status is associated with increased recurrence rates in patients with positive lymph-nodes. Notably, their cohort study identified 24.1% patients as HER2 (2C), whereas our cohort study identified only 12% patients as HER2 (2C). This difference might be due to the fact that Menard et al. made no distinction between HER2 (2C)/HER2C and HER2 (2C)/ HER2K tumors. Another explanation is the use of different IHC test systems. In other smaller studies with 1150 (Rossi et al. 2012 ) and 91 (Gilcrease et al. 2009 ) patients, HER2 (2C) and HER2 (1C) statuses, have also been reported to count as negative prognostic factor for DFS compared to HER2 (0) status.
Our results provide evidence that moderate expression of HER2 (2C) is biologically different from low and negative HER2 (0/1C) expression. We believe that the prognostic significance of moderate HER2 (2C) expression needs to be reevaluated as a predictor for anti-HER2 therapy. Notably, intratumoral heterogeneity of the HER2 gene is a characteristic property of tumors with low and moderate HER2 expression and is associated with decreased DFS (Barrett et al. 2007 , Seol et al. 2012 . Therefore, HER2 overexpression without gene amplification should be further evaluated, and the determination of the HER2 status and in particular the predictive value of HER2 (2C) expression should be reconsidered.
The main limitation of the present study is its retrospective character. However, this is a multicenter study with the largest cohort of HER2 (2C) cases to date. Our results suggest that HER2 (2C) tumors have a specific biological behavior associated with an unfavorable clinical outcome. The hypothesis that HER2 (2C) tumors might benefit from an anti-HER2 therapy is going to be addressed in a prospective clinical trial (NSABP-47 trial).
Declaration of interest E J Kantelhardt has research funding to disclose from Roche. C Thomssen has consulting and advisory role, honoraria, travel, and accommodations from Astra Zeneca, Roche, Amgen, Novartis, Celgene, and TEVA to disclose. All remaining authors have declared no conflicts of interest.
